Principal Investigator
Overview
Purpose of Study
This is an open label extension study for patients who participated in placebo-controlled dupilumab atopic dermatitis (AD) trials. The study primarily evaluates long term safety (adverse events) and immunogenicity. Efficacy parameters are based on Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI) and the Pruritus Numerical Rating Scale (NRS).
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.
Purpose of Study
This is an open label extension study for patients who participated in placebo-controlled dupilumab atopic dermatitis (AD) trials. The study primarily evaluates long term safety (adverse events) and immunogenicity. Efficacy parameters are based on Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI) and the Pruritus Numerical Rating Scale (NRS).
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.
